Veeva Systems Inc. (VEEV)

Veeva Systems builds the industry-specific cloud software that pharmaceutical and biotech companies use to run their operations — from CRM and regulatory submissions to clinical data management and quality control. Unlike horizontal SaaS (Salesforce, Workday), Veeva built vertically: every feature, every workflow, and every compliance module is designed for life sciences. This creates extraordinary switching costs: ripping out Veeva from a top-20 pharma's clinical operation is a multi-year, tens-of-millions-dollar project.

Veeva's AI strategy is to embed AI capabilities natively into its existing workflows — Veeva Vault AI for clinical data extraction, Veeva CRM Bot for sales force automation, and Vault Clinical Ops AI for site monitoring. The GLP-1 drug boom is a direct tailwind: Lilly, Novo Nordisk, Roche, and Pfizer are all Veeva customers expanding usage as they scale new drug franchises. Fiscal year 2026 (ending January 2026) revenue reached $3.2 billion, with the company having achieved its $3 billion run rate milestone. Q1 FY2027 revenue is guided to approximately $856.5 million.